

# PJ O'Brien & Associates

PO Box 916  
The Junction  
NSW 2291

23 December 2024

The Hon. Russell Broadbent MP  
Federal Member for Monash  
Parliament House  
Canberra ACT 2600

By email:

[Russell.Broadbent.MP@aph.gov.au](mailto:Russell.Broadbent.MP@aph.gov.au)

Attention: Mr Broadbent, MP

Dear Mr Broadbent

## **Urgent Request to Present Evidence of Synthetic DNA Contamination in Blood to the Prime Minister**

We refer to your [letters to Prime Minister Albanese](#) regarding evidence of synthetic DNA contamination in the Covid-19 Moderna and Pfizer vaccines sourced from Australia that Dr Speicher tested on our instruction for Federal Court proceedings.

### **1. Introduction**

- 1.1 We write to you with the utmost urgency regarding recent findings that significantly amplify the concerns surrounding the synthetic DNA contamination in the Pfizer and Moderna COVID-19 vaccines.
- 1.2 This new evidence confirms the same synthetic DNA contamination found in Australian sourced Covid-19 vials is in the blood of South Australian participants in a peer-reviewed study.
- 1.3 Given the detailed nature of the information contained in this letter, this letter is co-authored by experts in their field, drawn from the many co-signatories to this letter.
- 1.4 We urge you and the Senators copied on this correspondence to take immediate action to bring this critical development to the attention of the Prime Minister, the Minister for Health, and Professor Tony Lawler, Chief Medical Officer and Deputy Secretary of the Health Products Regulation Group.

**PJ O'Brien & Associates**

*Liability limited by a scheme approved under Professional Standards Legislation*

## 2. Confirmed Contamination in Australian Blood

- 2.1 Reanalysis of the raw data files of the Australian study led by Dr. [Ryan \(et al\)](#) revealed the presence of synthetic DNA fragments in the bloodstreams of 75 participants who had exclusively received Pfizer-BioNTech (BNT162b2) and/or Moderna (mRNA-1273) vaccines. These fragments include vaccine-derived DNA sequences including the SV40 promoter/enhancer sequence and kanamycin resistance genes, which were not removed during manufacturing.
- 2.2 Further genomic analysis of the raw data files by [Dr. Sandeep Chakraborty](#) (computational biologist) confirmed the presence of synthetic DNA in the blood of nearly all study participants. Genetic sequencing expert [Kevin McKernan's review](#) of the Ryan et al study highlighted that the sequencing methods used in this study likely under represented the amount of vaccine-derived DNA, raising the possibility of higher and potentially more harmful DNA fragment concentrations than identified in the data provided in this study.

## 3. Putative Findings of Genomic Integration and Replication

- 3.1 These findings are compounded by putative evidence from [Professor Philip Buckhaults](#) and [Kevin McKernan](#) that this synthetic DNA can and does integrate into human genomic DNA and can replicate within human cells. McKernan has further reported early-stage evidence of self-replication of the synthetic DNA within human cancer tumours, demonstrating a capacity for independent propagation.
- 3.2 Preliminary findings from a research team at [Yale University](#) led by Dr Iwasaki have detected synthetic spike protein in the blood of study participants more than two years after their final mRNA injection, raising concerns about the perdurance or capacity of the synthetic spike protein to endure indefinitely and the systemic nature of spike expression, potentially arising from genomic integration stemming from this synthetic DNA contamination.
- 3.3 The [Science Summary](#) you presented to the Prime Minister on 25 September 2024 specifically warned of the risks of genomic integration and replication. These warnings, unfortunately, appear to be materialising, with contamination now confirmed in South Australian blood samples. In light of these findings, it must be assumed that genomic integration has occurred within Australian recipients until conclusively proven otherwise.

#### **4. TGA's Delayed Response**

- 4.1 In light of recent revelations, it is concerning that the Therapeutic Goods Administration (**TGA**) has only recently begun to acknowledge the seriousness of this synthetic DNA contamination in mRNA vaccines. Internal emails, obtained through Freedom of Information (FOI) requests, reveal that as late as October 2024, TGA officials were still grappling with the implications of this contamination. These communications suggest a lack of urgency and a failure to fully appreciate the gravity and extent of the problem as highlighted in article from Rebekah Barnett, titled [\*Australian drug regulator knows DNA fragments in mRNA vaccines can enter nucleus and integrate into genome, internal emails show.\*](#)
- 4.2 Despite mounting evidence, the TGA has consistently sought to dismiss concerns about this DNA contamination as "misinformation". The article co-authored by Rebekah Barnett and several eminent scientists, doctors of medicine, and a former barrister, titled [\*Addressing Allegations that DNA Contamination Concerns Are Misinformation.\*](#) details how the TGA has characterised legitimate scientific findings as "baseless" or "false" without conducting independent validation of the data presented.
- 4.3 However, with the confirmation of synthetic DNA contamination in Australian blood samples, this dismissive stance is no longer tenable. Instead of dismissing concerns, the TGA must now confront the data and respond transparently.
- 4.4 Experts such as [Kevin McKernan](#) and [Dr. Jessica Rose](#) have criticised the TGA's approach, highlighting that the agency appears to be in serious catch-up mode regarding the science of this unique DNA contamination. This includes grappling with the risks of genomic integration and potential long-term health consequences, including cancers - risks that were previously dismissed but are now corroborated by findings in Australian blood samples and international studies.
- 4.5 These developments demand that the TGA urgently pivot from dismissive rhetoric to decisive action. The confirmed presence of synthetic DNA in Australian blood necessitates an immediate, transparent, and science-driven response to safeguard public health and to suitably manage the very vaccine hesitancy the Australian government is fostering.

#### **5. Recommendation to Seek Expert Advice from GTTAC**

- 5.1 In light of the profound implications of synthetic DNA contamination, it is imperative to acknowledge the limitations of the Therapeutic Goods Administration (TGA) in addressing the transfection products of Pfizer and Moderna vaccines. As evidenced in the FOI materials presented earlier, critical issues such as cytoplasmic interactions, nuclear entry pathways, genomic integration, and potential self-

replication of synthetic DNA fall outside the core expertise of the TGA. These are matters best suited to experts in nuclear biological sciences and gene technology.

- 5.2 The Office of the Gene Technology Regulator (OGTR) and especially its advisory body, the [Gene Technology Technical Advisory Committee](#) (GTTAC), possess the specialised expertise required to evaluate these critical issues.
- 5.3 The GTTAC is composed of distinguished experts from diverse fields, including genetics, molecular biology, oncology, and immunology. Their collective expertise makes them uniquely qualified to provide comprehensive advice on the ramifications of synthetic DNA contamination and its potential impact on human health.
- 5.4 The GTTAC is chaired by [Professor John Rasko AO](#), a globally recognised expert in gene and stem cell therapy, oncology, and molecular biology. Professor Rasko has pioneered advancements in translational medicine and has a longstanding commitment to ensuring the highest standards of safety and efficacy in biomedical research. Alongside him, the committee includes members such as:
  - Dr. Tessa Gargett: A leading researcher in immunotherapy, specialising in cellular therapies for cancer. Her expertise includes understanding transfection mechanisms used in therapeutic approaches, making her insights particularly relevant for evaluating synthetic DNA contamination in biological products.
  - Professor Jane Visvader: Recognised for her groundbreaking work in breast cancer research and stem cell biology. Her expertise in understanding how genetic elements influence tumorigenesis provides critical knowledge for assessing risks related to genomic integration.
  - Dr. Jason Smythe: An authority in molecular genetics and gene delivery systems, Dr. Smythe's experience is directly applicable to understanding transfection products and their potential pathways for integration within the human genome.
  - Professor Geraldine O'Neill: Specializes in cellular and molecular biology with a focus on disease modelling. Her research includes studying cellular mechanisms that could be disrupted by genomic integration, making her insights invaluable for understanding the systemic risks posed by synthetic DNA contamination.
- 5.5 These are just a few examples of the GTTAC's esteemed membership, which collectively represents an unparalleled resource for understanding and addressing the ramifications of synthetic DNA contamination in biological products.
- 5.6 We respectfully submit that the Prime Minister, Minister for Health, and Chief Medical Officer should engage with the GTTAC to obtain comprehensive, science-based evaluations of the emerging evidence. The GTTAC's expertise will ensure that

Australia's response to this crisis is informed by the most authoritative scientific advice available, thereby safeguarding public health and restoring trust in regulatory oversight.

## **6. Actionable Steps**

6.1 We implore you, Mr. Broadbent, and the Senators copied on this letter to:

- a. **Present These Findings to the Prime Minister:** Request an immediate response to this national health concern and urge the Prime Minister to engage the most qualified body of experts to assess the implications and provide recommendations.
- b. **Seek Guidance from the GTTAC:** Recommend the Prime Minister, Minister for Health, and Chief Medical Officer formally consult with the Gene Technology Technical Advisory Committee to obtain comprehensive, science-based evaluations of the emerging evidence. The GTTAC's expertise in genetic transfection technologies, genomic integration, and their associated risks - including the potential for long-term adverse outcomes such as cancers - positions it as the most appropriate advisory body for this crisis.
- c. **Coordinate Efforts with International Leaders:** Inform Australia's allies and global health bodies of these findings to encourage a collaborative and science-driven approach to understanding and addressing synthetic DNA contamination.

6.2 The issues here transcend political divisions and demands a united, evidence-based response. The confirmed contamination of Australian blood with synthetic DNA necessitates swift and decisive action to safeguard public health and restore public confidence. Engaging the GTTAC will not only ensure that Australia's actions are guided by the highest level of scientific expertise but will also address the public's concerns regarding the long-term implications of this contamination. By taking these steps, the government can demonstrate its commitment to protecting the health of all Australians and lead the way in addressing what may prove to be a global health challenge.

6.3 Thank you for your attention to this critical matter. We trust you will act with urgency to bring these findings to the highest levels of government. Please do not hesitate to contact me should you require further information or support.

6.4 Your continuing efforts to raise this issue with the Prime Minister and within Parliament are commendable, and we are grateful for your leadership in advocating for transparency and public safety.

Thank you for your attention to this urgent matter.

We look forward to your response.

Yours sincerely,



Katie Ashby-Koppens  
**PJ O'Brien & Associates**  
[katie@pjob.com.au](mailto:katie@pjob.com.au)

CC

*Senator Malcolm Roberts:* [senator.roberts@aph.gov.au](mailto:senator.roberts@aph.gov.au)  
*Senator Alex Antic:* [senator.antic@aph.gov.au](mailto:senator.antic@aph.gov.au)  
*Senator Ralph Babet:* [senator.babet@aph.gov.au](mailto:senator.babet@aph.gov.au)  
*Senator Gerard Rennick:* [senator.rennick@aph.gov.au](mailto:senator.rennick@aph.gov.au)  
*Senator Pauline Hanson:* [senator.hanson@aph.gov.au](mailto:senator.hanson@aph.gov.au)  
*Senator Matt Canavan:* [senator.canavan@aph.gov.au](mailto:senator.canavan@aph.gov.au)

## **Co-signatories**

### **Emeritus Prof Angus Dalgleish**

MD FRACP FRCP FRCPath FMedSci

Emeritus Prof of Oncology University of London, Principal of the Institute of cancer vaccines and immunotherapy (ICVI)

### **Emeritus Prof Wendy Hoy**

Professor of Medicine, FAA AO FRACP

MBBS(H1) BScMed (H1)

University of Queensland

### **Emeritus Professor Sucharit Bhakdi**

M.D.

### **Kevin McKernan**

BSc, (Former) Research Director

Human Genome Project

### **Prof Alexandra Henrion Caude**

Geneticist, (Former) Director of Research INSERM French National Institute of Health and Medical Research, Paris, France

### **Prof Ian Brighthope**

Director, The World of Wellness International

Advisor, The Aligned Council of Australia

### **Prof Robyn Cosford**

MBBS(Hons), DipNutr, Dip Hom, FACNEM

FASLM, Professor of Nutritional and

Environmental Medicine

Chair, Children's Health Defense

### **Professor Paul Frijters**

Economics

### **Prof Gigi Foster**

Co-Director, Australians for Science and

Freedom

University of New South Wales

### **Prof Brendan Vote**

Director, Tasmanian Eye Institute Ltd

Clinical Professor

University of Tasmania

### **PJ O'Brien & Associates**

*Liability limited by a scheme approved under Professional Standards Legislation*

**Prof Kylie O'Brien PhD**  
Clinical Researcher  
Consultant in Integrative Medicine  
Consultant in Higher Education

**Professor Eleftherios Gkioulekas**  
Professor of Mathematics  
University of Texas Rio Grande Valley

**A/Prof Peter Parry**  
MBBS, PhD, FRANZCP, Cert. Child & Adolesc. Psychiatry, University of Queensland

**A/Prof Jonathan D Gilthorpe**  
BSc (Hons), PhD, Docent  
Senior Lecturer  
Umeå University, Sweden

**A/Prof Michael Sladden**  
MBChB, MAE, MRCP, FACD, FRACGP  
MRCGP, Consultant Dermatologist  
Associate Professor Medicine and Dermatology, University of Tasmania

**A/Prof Maarten Fornerod, PhD**  
Associate professor of Cell Data and Disease  
Biomedical Sciences  
Erasmus University Medical Center  
Rotterdam, The Netherlands

**Dr Elvis Ivan Šeman**  
MBBS, FRANZCOG, EUCOGE, FRCOG, NFPMC, PhD  
Adjunct Associate Professor, College of Medicine and Public Health, Flinders University,  
South Australia  
Medical Director, MaterCare International

**Dr Jessica Rose, PhD**  
Applied Mathematics,  
Immunology, Computational Biology  
Biochemistry, Molecular Biology

**Dr David J. Speicher**  
Virologist, PhD DTM  
Senior Research Associate  
University of Guelph, Canada



**Dr Melissa McCann**

BPharm MBBS FRACGP

**Dr Ciara O'Sullivan**

MBBS, BSc, MRCP (London), FRACP

**Dr Angela Jeanes**

BSc(Hons), PhD

**Dr Julie Sladden**

MBBS(Hons), BMedSci

PGDipMedEd

**Dr Deirdre Little**

MBBS DRANZCOG FACRRM

**Dr Christopher Neil**

MBBS, FRACP, PhD

Cardiologist

President, Australian Medical Professionals Society

**Dr Jeyanthi Kunadhasan**

MD (UKM), MMed (AnaesUM), FANZCA MMED

**Dr Luke McLindon**

MBBS FRACGP FRANZCOG

Obstetrician & Gynaecologist

Advanced Laparoscopy/Endometriosis/Infertility

**Dr Niroshan Sivathasan**

BSc, MB BS (Lond), DRCOG, MRCS (Eng), AFACP, DU (Plast), FCPCA, FACAM, FACCSM (Med), FACCSM (Surg), FAACS.

**Dr Conny Turni**

BSc, Hons, PhD

Senior Research Fellow

Microbiology Research

QAAFI, University of Queensland

**Dr Gary Fettke**

Retired Orthopaedic Surgeon

M.B.,B.S.(University NSW), F.R.A.C.S.(Orthopaedic Surgery), F.A.Orth.A., MHP

**Dr Paul Oosterhuis**  
MBBS FANZCA

**Dr. Marsha Y. Blakeslee D.O.**  
Internal Medicine

**Dr Judy Soper**  
MBBS, FRANZCR

**Dr. Varghese Zachariah**  
FRACGP, DCH, AFMCP

**Dr Nicholas J. Hudson, PhD**  
Senior lecturer in Metabolic Biochemistry  
University of Queensland

**Dr Astrid Lefringhausen**  
PhD Molecular Biology and Biochemistry  
Specialised in Virology and Immunology  
Board of Directors CHD Australia

**Dr Andrew Madry**  
BSc PhD

**Dr Suzanne Niblett**  
BSc (Hons), PhD

**Dr Phillip Altman**  
BPharm(Hons), MSc, PhD  
Clinical Trial and Regulatory Affairs Consultant

**Dr Duncan Syme**  
MBBS FRACGP DROGG Dip Practical

**Dr Andrew McIntyre**  
Consultant Gastroenterologist  
FRACP MBBS(Hons)

**Dr Sally Price**  
MBBS FACNEM FASLM

**Dr Valerie Peers**  
MBBS DRANZVOG

**Dr Hans Peter Dietz**

MD PhD FRANZCOG DDU CU  
Obstetrician, Gynaecologist and Urogynaecologist

**Dr Julian Fidge**

BPharm, Grad Dip App Sc (Comp Sc)  
MBBS, FRACGP, MMed (Pain Mgt)

**Dr Jan Heath**

B.A. (Soc Sci), B.A. (Hons), M.Psych  
(Counselling), M.Terr&Sec Stud, D.Psych  
(Forensic), MAPS, FCFP

**Dr Michelle Musca**

MBBS FRACGP

**Dr Carmen Trill**

FRACGP Adv DRANZCOG

**Dr Beverley Peers**

FANZCA

**Dr Serene Lim**

MBBS

**Dr Marc Rendell, M.D.**

**Dr John Anderson**

MBBS

**Dr Peter Johnston**

MMBS FRACGP

**Dr Gina Eddy**

B Med Sci MBBS FRACGP FACNEM

**Dr Mary Kelly Sutton, M.D.**

**Dr Geoff Pain**

PhD. B.Sc.(Hons.)  
Grad Dipl Business Management

**Christof Plothe DO**  
BSC.(OST), HONS

**Dr Catherine Fyans**  
MBBS

**Kara Thomas**  
BNurs, GCertNurs, MInt&CommDev

**Bernadette Ryan**  
BSW, Grad Dip Com

**Peter Fam**  
LLB, Human Rights Lawyer  
Principal Partner, MAATs Methods

**Julian Gillespie**  
LLB, BJuris